Staff Directory

Filter By Surname
Filter By Position
Filter By Keyword
Filter By Cancer Type
Search
Professor Kairbaan Hodivala-Dilke
Deputy Institute Director, Professor of the Tumour Microenvironment

Our research aims to improve the efficacy of standard of care immunotherapy, chemotherapy and radiotherapy in human solid cancers by understanding the molecular mechanisms underlying tumour stromal contributions to tumour growth and therapy efficacy.

Dr Özgen Deniz
Lecturer

Our research aims to understand the epigenetic regulation of transposable elements and how their dysregulation contributes to the generation and development of cancer. In particular, we investigate their roles as gene regulators and triggers of anti-tumour immunity in blood cancers.

Professor Marco Gerlinger
Professor of Gastrointestinal Cancer Medicine; Consultant Medical Oncologist and Director of GI Cancer Research at St. Bartholomew's Hospital

We are investigating how drug resistance evolves in bowel and gastro-oesophageal cancers, how these tumour types can be treated more effectively through novel immunotherapies and targeted drugs, and how treatment sensitivity and resistance can be predicted.

Professor Richard Grose
Professor of Cancer Cell Biology

We are interested in how cancer cells interact with each other and the microenvironment. We investigate how cancer cell communication with neighbouring stromal cells and the extracellular matrix can impact on invasion and response to targeted therapies, to try to block cancer progression, with a particular focus on breast and pancreatic cancer.

Dr Ioanna Keklikoglou
Lecturer

Our group focuses on understanding the molecular and cellular mechanisms that mediate resistance to anti-cancer therapies in breast cancer. We are interested in dissecting the microenvironmental cues that orchestrate specific tumour responses and metastasis formation.

Professor Michelle Lockley
Clinical Professor of Medical Oncology, Honorary Consultant

Our lab aims to improve treatments for women with ovarian cancer, particularly those that are resistant to chemotherapy. We are interested in developing therapies that can adapt to the evolution of chemotherapy resistance over time such as Adaptive Therapy.

Dr Marta Buzzetti

My research focuses on the use of patient-derived organoid co-cultures and genome wide CRISPR screens to unravel tumour intrinsic gene networks controlling resistance to CD3 bispecific antibodies in colorectal cancer, and possibly applicable to other tumour types.

Dr Eve Coulter

My research focuses on novel strategies to enrich, isolate and characterise a chemo-resistant population in patients with follicular lymphoma.

Dr Vilma Dembitz

My research is focused on the role of lipid metabolism in resistance to therapy in acute myeloid leukemia.

Dr Katarina Kluckova

We are interested in metabolic dependencies of B-cell lymphomas, in particular the serine synthesis pathway and one carbon metabolism.

Dr Ana Levi

My focus is on investigating the epigenetic regulation of the PI3K pathway and identifying an effective combination therapy that will disable compensatory bypass routes, overcoming drug resistance.

Dr Audrey Lumeau

My research focuses on understanding the relationship between chromosome instability mechanisms and tumour cells’ resistance to therapies.

Dr Celine Philippe

My project focuses on the translation reprogramming in acute myeloid leukaemia upon stresses such as chemotherapy.

Dr Laura Wisniewski

My project looks at the modelling of cancer for improved therapy development. I am carrying out in vivo cancer experiments, with and without modifications of the tumour microenvironment, to examine effects of such treatments on anti-cancer therapy efficacy.